<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5724">
  <stage>Registered</stage>
  <submitdate>27/02/2015</submitdate>
  <approvaldate>27/02/2015</approvaldate>
  <nctid>NCT02378935</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection</studytitle>
    <scientifictitle>A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-367-1168</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C Virus Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GS-9857
Treatment: drugs - SOF/VEL
Treatment: drugs - RBV

Experimental: GS-9857+SOF/VEL 6 wk, TN, without cirrhosis - GS-9857 + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)

Experimental: GS-9857+SOF/VEL 8 wk, TN, without cirrhosis - GS-9857 + SOF/VEL for 8 weeks (treatment naive (TN), without cirrhosis)

Experimental: GS-9857+SOF/VEL 6 wk, TN, with cirrhosis - GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)

Experimental: GS-9857+SOF/VEL 8 wk, TN, with cirrhosis - GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)

Experimental: GS-9857+SOF/VEL+RBV 8 wk, TN, with cirrhosis - GS-9857 + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)

Experimental: GS-9857+SOF/VEL 8 wk, without cirrhosis - GS-9857 + SOF/VEL for 8 weeks (failed prior treatment, without cirrhosis)

Experimental: GS-9857+SOF/VEL 12 wk, without cirrhosis - GS-9857 + SOF/VEL for 12 weeks (failed prior treatment, without cirrhosis)

Experimental: GS-9857+SOF/VEL 8 wk, with cirrhosis - GS-9857 + SOF/VEL for 8 weeks (failed prior treatment, with cirrhosis)

Experimental: GS-9857+SOF/VEL 12 wk, with cirrhosis - GS-9857 + SOF/VEL for 12 weeks (failed prior treatment, with cirrhosis)

Experimental: GS-9857+SOF/VEL 12 wk (GS-US-338-1121) - GS-9857 + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)


Treatment: drugs: GS-9857
GS-9857 100 mg tablet administered orally once daily with food

Treatment: drugs: SOF/VEL
SOF/VEL (400/100 mg) FDC tablet administered orally once daily with food

Treatment: drugs: RBV
RBV tablets administered orally in a divided daily dose according to weight-based dosing recommendations (&lt; 75kg = 1000 mg and = 75 kg = 1200 mg)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12) - SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</outcome>
      <timepoint>Posttreatment Week 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of any adverse events leading to permanent discontinuation of study drug(s)</outcome>
      <timepoint>Up to 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24) - SVR4 and SVR24 are defined as HCV RNA &lt; LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.</outcome>
      <timepoint>Posttreatment Weeks 4 and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome>
      <timepoint>Up to 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HCV RNA change from baseline</outcome>
      <timepoint>Up to 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The proportion of participants with virologic failure - On treatment virologic failure is defined as:
HCV RNA = LLOQ after having previously had HCV RNA &lt; LLOQ, while on treatment, confirmed with 2 consecutive values or last available on-treatment measurement with no subsequent follow-up values (ie, breakthrough)
&gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values or last available on-treatment measurement with no subsequent follow-up values (ie, rebound)
HCV RNA persistently = LLOQ through 8 weeks of treatment (ie, nonresponse)
Relapse is defined as:
HCV RNA = LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</outcome>
      <timepoint>Up to Posttreatment Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Individuals with chronic HCV infection

          -  HCV RNA =10^4 IU/mL at screening

          -  HCV genotype 1

          -  Cirrhosis determination; a liver biopsy may be required

          -  Screening laboratory values within defined thresholds

          -  Use of two contraception methods if female of childbearing potential or sexually
             active male</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or nursing female

          -  Current or prior history of hepatic decompensation

          -  Hepatocellular carcinoma (HCC) or other clinically significant malignancy

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  History of clinically significant illness or any other medical disorder that may
             interfere with the individual's treatment, assessment or compliance with the protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>205</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety, tolerability, and efficacy of GS-9857 plus sofosbuvir
      (SOF)/velpatasvir (VEL) fixed dose combination (FDC) Â± ribavirin (RBV) in adults with chronic
      genotype 1 hepatitis C virus (HCV) infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02378935</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jenny Yang, PharmD</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>